Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product ...
Pharmabiz3d
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...
FiercePharma21h
Catalyst settles with Teva, staving off Firdapse generic until 2035
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
Santhera Pharmaceuticals Holding AG: Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) ...
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...
PharmiWeb29d
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and ...
Morningstar21d
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older Follows recent approval from China’s National ...
manilatimes21d
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Pratteln, Switzerland, December 20, 2024 - Santhera Pharmaceuticals (SIX: SANN) announces that the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged ...